PURPOSE: High-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) have been used for the treatment of clinically aggressive non-Hodgkin's lymphoma (NHL). However, the superiority of specific conditioning regimens has not yet been established. The present study evaluated the efficacy and toxicity of a conditioning regimen involving fractionated total body irradiation (TBI), and the use of Ara-C and melphalan (TAM) for clinically aggressive NHL. MATERIALS AND METHODS: Between March 2002 and December 2004, 31 patients with aggressive NHL received fractionated TBI with a dose of 12 Gy over 3 days, and were administered 9 g/m(2) Ara-C and 100 mg/m(2) melphalan followed by autologous peripheral blood stem Cell Transplantation at the Catholic Hematopoietic Stem cell transplantation Center Korea. Patients that responded to first line chemotherapy and achieved complete remission (CR), or were in a first sensitive relapse were defined as having less advanced disease, while the other patients were defined as having more advanced disease. RESULTS: Objective responses were obtained in 24 of 31 patients (77.4%), comprising complete remission in 19 patients (61.3%) and partial remission in 5 (16.1%) patients. The median follow-up time was 28 months (range 1 approximately 62 months). At 3 years, the overall survival and event-free survival (EFS) rates were 62.3% and 47.3%, respectively. Patients with less advanced disease and more advanced disease showed 3-year EFS rates of 73.3% and 22.5 %, respectively (p=0.006). Early (within the first 100 days) treatment-related mortality occurred in 3 (9.7%) patients. Of the 31 total patients, 15 (48.4%) developed grade 3 mucositis, 22 (70.9%) developed neutropenic fever, and two (6.5%) developed interstitial pneumonia syndrome>grade 3. CONCLUSION: The modified TAM conditioning regimen and ASCT appear to be a feasible treatment regimen for clinically aggressive NHL, particularly for patients with less advanced disease.
PURPOSE: High-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) have been used for the treatment of clinically aggressive non-Hodgkin's lymphoma (NHL). However, the superiority of specific conditioning regimens has not yet been established. The present study evaluated the efficacy and toxicity of a conditioning regimen involving fractionated total body irradiation (TBI), and the use of Ara-C and melphalan (TAM) for clinically aggressive NHL. MATERIALS AND METHODS: Between March 2002 and December 2004, 31 patients with aggressive NHL received fractionated TBI with a dose of 12 Gy over 3 days, and were administered 9 g/m(2) Ara-C and 100 mg/m(2) melphalan followed by autologous peripheral blood stem Cell Transplantation at the Catholic Hematopoietic Stem cell transplantation Center Korea. Patients that responded to first line chemotherapy and achieved complete remission (CR), or were in a first sensitive relapse were defined as having less advanced disease, while the other patients were defined as having more advanced disease. RESULTS: Objective responses were obtained in 24 of 31 patients (77.4%), comprising complete remission in 19 patients (61.3%) and partial remission in 5 (16.1%) patients. The median follow-up time was 28 months (range 1 approximately 62 months). At 3 years, the overall survival and event-free survival (EFS) rates were 62.3% and 47.3%, respectively. Patients with less advanced disease and more advanced disease showed 3-year EFS rates of 73.3% and 22.5 %, respectively (p=0.006). Early (within the first 100 days) treatment-related mortality occurred in 3 (9.7%) patients. Of the 31 total patients, 15 (48.4%) developed grade 3 mucositis, 22 (70.9%) developed neutropenic fever, and two (6.5%) developed interstitial pneumonia syndrome>grade 3. CONCLUSION: The modified TAM conditioning regimen and ASCT appear to be a feasible treatment regimen for clinically aggressive NHL, particularly for patients with less advanced disease.
Entities:
Keywords:
Autologous stem cell transplantation; High dose therapy; Non-Hodgkin's lymphoma; TAM conditioning
Authors: A Salar; J Sierra; M Gandarillas; M D Caballero; J Marín; J J Lahuerta; J García-Conde; R Arranz; A León; J Zuazu; J García-Laraña; A López-Guillermo; M A Sanz; A Grañena; J C García; E Conde Journal: Bone Marrow Transplant Date: 2001-02 Impact factor: 5.483
Authors: J M Vose; M J Zhang; P A Rowlings; H M Lazarus; B J Bolwell; C O Freytes; S Pavlovsky; A Keating; B Yanes; K van Besien; J O Armitage; M M Horowitz Journal: J Clin Oncol Date: 2001-01-15 Impact factor: 44.544
Authors: F Gutierrez-Delgado; D G Maloney; O W Press; J Golden; L A Holmberg; R T Maziarz; H Hooper; C D Buckner; F R Appelbaum; W I Bensinger Journal: Bone Marrow Transplant Date: 2001-09 Impact factor: 5.483
Authors: S I Bearman; F R Appelbaum; C D Buckner; F B Petersen; L D Fisher; R A Clift; E D Thomas Journal: J Clin Oncol Date: 1988-10 Impact factor: 44.544
Authors: O W Press; J F Eary; T Gooley; A K Gopal; S Liu; J G Rajendran; D G Maloney; S Petersdorf; S A Bush; L D Durack; P J Martin; D R Fisher; B Wood; J W Borrow; B Porter; J P Smith; D C Matthews; F R Appelbaum; I D Bernstein Journal: Blood Date: 2000-11-01 Impact factor: 22.113
Authors: F R Appelbaum; K M Sullivan; C D Buckner; R A Clift; H J Deeg; A Fefer; R Hill; J Mortimer; P E Neiman; J E Sanders Journal: J Clin Oncol Date: 1987-09 Impact factor: 44.544
Authors: Q Y Dai; G Souillet; Y Bertrand; C Galambrun; N Bleyzac; A M Manel; B Bruno; A L Souillet; E Homole; M P Pages; P Berlier; M David; J C Berthier; B Massenavette; B Contamin; N Philippe Journal: Bone Marrow Transplant Date: 2004-10 Impact factor: 5.483